Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7486967 safety, pharmacokinetics, and pharmacodynamics study in early idiopathic Parkinson's disease
NL-OMON59563Phase 1Completed
- Sponsor
- Roche
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of selnoflast in Parkinson's disease (PD), sponsored by Roche. Primary endpoint: Primary endpoint(s). Started Sep 2022; status: completed.
02
Drugs
selnoflast
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON59563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59563.